A multicenter study led by scientists at Monash Institute of Pharmaceutical Sciences in Melbourne, Australia, has described a new mesenteric lymph vessel-based pathogenic mechanism, which was shown to contribute to visceral fat accumulation and insulin resistance in both mice and humans.
